[Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus].

Autor: Tsygankova OV; Novosibirsk State Medical University, Novosibirsk, Russia Research Institute of Therapy and Preventive Medicine, Branch of the Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia., Veretyuk VV; Centers of Family Medicine 'Zdravnitsa', Ltd., Novosibirsk, Russia., Mareev VY; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia.

Publikováno v: Kardiologiia [Kardiologiia] 2020 Jun 03; Vol. 60 (5), pp. 840. Date of Electronic Publication: 2020 Jun 03.